Global Streptokinase Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Streptokinase Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Streptokinase is indicated for the treatment of AMI, acute massive pulmonary embolism (PE), deep vein thrombosis (DVT), arterial thrombosis, and occluded arteriovenous cannulae.
Streptokinase report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Streptokinase market is projected to reach US$ 526.1 million in 2029, increasing from US$ 364 million in 2022, with the CAGR of 5.9% during the period of 2024 to 2029. Demand from Myocardial Infarction (MI) and Deep Vein Thrombosis are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Streptokinase industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029.
Globally, Streptokinase key manufacturers include SAMARTH PHARMA, Biocon, Kee Pharma, Dabur, Biosena, Wanbang Biopharma, Qingdao GD Biotechnology Pharmaceutical, Aristo Pharmaceuticals and Neiss Labs, etc. SAMARTH PHARMA, Biocon, Kee Pharma are top 3 players and held % sales share in total in 2022.
Streptokinase can be divided into High IU and Low IU, etc. High IU is the mainstream product in the market, accounting for % sales share globally in 2022.
Streptokinase is widely used in various fields, such as Myocardial Infarction (MI), Deep Vein Thrombosis, Pulmonary Embolism and Others, etc. Myocardial Infarction (MI) provides greatest supports to the Streptokinase industry development. In 2022, global % sales of Streptokinase went into Myocardial Infarction (MI) filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Streptokinase market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
SAMARTH PHARMA
Biocon
Kee Pharma
Dabur
Biosena
Wanbang Biopharma
Qingdao GD Biotechnology Pharmaceutical
Aristo Pharmaceuticals
Neiss Labs
Ahaan Healthcare Pvt Ltd. (AHPL)
Biofactor
TTK HealthCare
Incepta Pharmaceuticals Limited
Cadila
Segment by Type
High IU
Low IU
Myocardial Infarction (MI)
Deep Vein Thrombosis
Pulmonary Embolism
Others
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Streptokinase market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Streptokinase, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Streptokinase industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Streptokinase in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Streptokinase introduction, etc. Streptokinase Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports Conclusions of Streptokinase market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Streptokinase report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Streptokinase market is projected to reach US$ 526.1 million in 2029, increasing from US$ 364 million in 2022, with the CAGR of 5.9% during the period of 2024 to 2029. Demand from Myocardial Infarction (MI) and Deep Vein Thrombosis are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Streptokinase industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029.
Globally, Streptokinase key manufacturers include SAMARTH PHARMA, Biocon, Kee Pharma, Dabur, Biosena, Wanbang Biopharma, Qingdao GD Biotechnology Pharmaceutical, Aristo Pharmaceuticals and Neiss Labs, etc. SAMARTH PHARMA, Biocon, Kee Pharma are top 3 players and held % sales share in total in 2022.
Streptokinase can be divided into High IU and Low IU, etc. High IU is the mainstream product in the market, accounting for % sales share globally in 2022.
Streptokinase is widely used in various fields, such as Myocardial Infarction (MI), Deep Vein Thrombosis, Pulmonary Embolism and Others, etc. Myocardial Infarction (MI) provides greatest supports to the Streptokinase industry development. In 2022, global % sales of Streptokinase went into Myocardial Infarction (MI) filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Streptokinase market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
SAMARTH PHARMA
Biocon
Kee Pharma
Dabur
Biosena
Wanbang Biopharma
Qingdao GD Biotechnology Pharmaceutical
Aristo Pharmaceuticals
Neiss Labs
Ahaan Healthcare Pvt Ltd. (AHPL)
Biofactor
TTK HealthCare
Incepta Pharmaceuticals Limited
Cadila
Segment by Type
High IU
Low IU
Segment by Application
Myocardial Infarction (MI)
Deep Vein Thrombosis
Pulmonary Embolism
Others
Segment by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Streptokinase market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Streptokinase, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Streptokinase industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Streptokinase in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Streptokinase introduction, etc. Streptokinase Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports Conclusions of Streptokinase market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices